Nuvation Bio Inc. clinical trials
The registry lists 20 studies whose lead sponsor is Nuvation Bio Inc. or one of 1 company grouped under it. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 10, 2026.
Our grouping of 2 registry names, not the registry’s. See them and correct one ↓
- 20studies on the registry
- 6open to participants now
- 4phase 3 studies under way
- 2reach primary completion within a year
Get an email when these change. Save the Nuvation Bio Inc. studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
What it is testing
The drugs Nuvation Bio Inc.’s studies test, most open studies first — 4 drugs with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
- taletrectinib2 in phase 33 open · 9
- safusidenib2 in phase 33 open · 4
- 0 open · 3
- 0 open · 1
Coming up
2 of Nuvation Bio Inc.’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- JJan ’27’27
- 1FFeb
- 1MMar
- AApr
- MMay
- JJun
- JJul
- AAug
- SSep
- OOct
- NNov
All 2
Add all 2 to your calendar (.ics) → With an account.
What changed recently
From the registry's own updates since Oct 14, 2026.
Started recruiting1
All 20 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 421
- 22
- 23
- 24
- 25
- 126
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Nuvation Bio Inc..
Studies
Recruiting first, then most recently updated. Showing 20 of 20.
- Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive DiseaseRecruitingNCT07703436Phase 2
- SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)RecruitingNCT05303519Phase 3
- Study on the Effect of Famotidine on Pharmacokinetics of TaletrectinibNot yet recruitingNCT07742384Phase 1
- Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant GliomaNot yet recruitingNCT07712757Phase 3
- Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)RecruitingNCT07154706Phase 3
- A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer PatientsRecruitingNCT06564324Phase 3
- A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion GeneActive, not recruitingNCT04395677Phase 2
- Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene FusionTerminatedNCT04617054Phase 2
- Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid TumorsActive, not recruitingNCT06334432Phase 1/2
- Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLCActive, not recruitingNCT04919811Phase 2
- Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLCNo longer availableNCT06841874
- NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid TumorsTerminatedNCT05252390Phase 1
- A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051bCompletedNCT02279433Phase 1
- A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PKCompletedNCT05357820Phase 1
- Study the Effect of Omeprazole on AB-106 PharmacokineticsCompletedNCT05609929Phase 1
- A Study on the Effect of AB-106 on the Pharmacokinetics of DigoxinCompletedNCT05357911Phase 1
- IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid TumorTerminatedNCT05814536Phase 1
Sponsor listed in the registry: AnHeart Therapeutics Inc. · First submitted before AnHeart Therapeutics Inc. became part of Nuvation Bio Inc.
- Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid TumorsTerminatedNCT04541225Phase 1
- Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBCWithdrawnNCT05191004Phase 1/2
- Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPCWithdrawnNCT05191017Phase 1/2